Additional file 1: of A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial

Figure S1. Study Design: After the informed consent and screening visits patients were randomized in a 1:1 ratio and treated with SB010 mg bid or matching placebo via AKITA inhalation for 28 days. A follow-up visit was conducted 4 weeks after termination of IMP treatment. (JPEG 48 kb)